Cargando…

Protection against Reinfection with the Omicron BA.2.75 Subvariant

Detalles Bibliográficos
Autores principales:	Chemaitelly, Hiam, Tang, Patrick, Coyle, Peter, Yassine, Hadi M., Al-Khatib, Hebah A., Smatti, Maria K., Hasan, Mohammad R., Ayoub, Houssein H., Altarawneh, Heba N., Al-Kanaani, Zaina, Al-Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar H., Latif, Ali N., Shaik, Riyazuddin M., Abdul-Rahim, Hanan F., Nasrallah, Gheyath K., Al-Kuwari, Mohamed G., Butt, Adeel A., Al-Romaihi, Hamad E., Al-Thani, Mohamed H., Al-Khal, Abdullatif, Bertollini, Roberto, Abu-Raddad, Laith J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878583/ https://www.ncbi.nlm.nih.gov/pubmed/36652342 http://dx.doi.org/10.1056/NEJMc2214114

Ejemplares similares

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections
por: Qassim, Suelen H, et al.
Publicado: (2022)

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
por: Altarawneh, Heba N., et al.
Publicado: (2022)

1966. Protection afforded by prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections.
por: Altarawneh, Heba N, et al.
Publicado: (2022)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Covid-19 Vaccine Protection among Children and Adolescents in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
por: Ayoub, Houssein H, et al.
Publicado: (2021)

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
por: Seedat, Shaheen, et al.
Publicado: (2021)

COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
por: Altarawneh, Heba N., et al.
Publicado: (2023)

Duration of immune protection of SARS-CoV-2 natural infection against reinfection
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
por: Abu-Raddad, Laith J, et al.
Publicado: (2021)

Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar’s experience
por: Bsat, Raghid, et al.
Publicado: (2022)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
por: Qassim, Suelen H., et al.
Publicado: (2023)

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
por: Abu-Raddad, Laith J, et al.
Publicado: (2021)

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

History of primary-series and booster vaccination and protection against Omicron reinfection
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections
por: Qassim, Suelen H., et al.
Publicado: (2022)

SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
por: Mahmoud, Mai A., et al.
Publicado: (2023)

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
por: Abu-Raddad, Laith J, et al.
Publicado: (2020)

Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population
por: Nasrallah, Gheyath K., et al.
Publicado: (2021)

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2
por: Coyle, Peter V., et al.
Publicado: (2022)

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
por: Coyle, Peter V., et al.
Publicado: (2021)

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
por: Tayar, Elias, et al.
Publicado: (2023)

Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
por: Jeremijenko, Andrew, et al.
Publicado: (2021)

All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
por: AlNuaimi, Asma A, et al.
Publicado: (2023)

Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020
por: Al Kuwari, Hanan M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l9a5gb6sv9rohbt4m46c0r17ph